HOME_PAGE_HEADER_CONTENT

A female patient and a female physician, representing different ethnicities in conversation A female patient and a female physician, representing different ethnicities in conversation

Passion for Innovation.
Compassion for Patients.®

Creating New Standards of Care

Creating New Standards of Care

We create essential medicine for longer, better lives.

Learn More About Our Purpose

RecentStoryCarousel

Our Stories

Everyone at Daiichi Sankyo has a unique craft - a skill or expertise that they hone with relentless dedication. Our inclusive and diverse community of collaborators apply their individual expertise with compassion to innovate for patients. View More Stories

Understanding Metastatic Breast Cancer: Exploring the Science

Not all breast cancers are the same. This is particularly true about metastatic breast cancer versus early-stage breast cancer in terms of how the disease spreads, its prognosis, treatment options, and even the patient journey.

Learn more
Cherry Blossoms in Washington, D.C. Source of Pride for Daiichi Sankyo

Daiichi Sankyo honors its Japanese heritage and connection to the cherry blossom trees in Washington, D.C. as a perennial sponsor of the National Cherry Blossom Festival. Learn about the special link and watch a video capturing the joy felt by Daiichi Sankyo employees participating in the festival parade.

Learn more

Transforming Science into Medicines

Transforming Science into Medicines

By uniting cutting-edge science and technology with a genuine interest in people, we develop high-quality, life-changing solutions for the patients of today and tomorrow with great care and unwavering dedication.

Learn More About Our Science
2 women in lab coats looking at a sample

Dxd Section

Striving to Create Optimized Antibody Drug Conjugate (ADC) Technology

DXd ADC Technology: Our innovations deliver on the benefits of ADC technology.

Explore the DXd ADC Technology Website

Featured News

What's New

Read our press releases and learn more about our latest breakthroughs in medicine. View More News

Sat May 31 00:00:00 GMT-05:00 2025

ENHERTU® Reduced the Risk of Death by 30% Versus Ramucirumab Plus Paclitaxel as a Second-Line Therapy in Patients with HER2 Positive Unresectable or Metastatic Gastric Cancer in DESTINY-Gastric04 Phase 3 Trial

Daiichi Sankyo and AstraZeneca’s ENHERTU demonstrated a median overall survival of 14.7 months Results reinforce second-line use of ENHERTU globally in this setting

Learn more

Thu May 29 00:00:00 GMT-05:00 2025

Patritumab Deruxtecan Biologics License Application for Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer Voluntarily Withdrawn

The Biologics License Application (BLA) seeking accelerated approval in the US for Daiichi Sankyo (TSE: 4568) and Merck’s (NYSE: MRK), known as MSD outside of the United States and Canada, patritumab deruxtecan (HER3-DXd) based on the HERTHENA-Lung01 phase 2 trial for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with two or more systemic therapies has been voluntarily withdrawn.

Learn more

New Home Pipeline

A Pipeline Pushing Us to Become a Global Leader in Oncology

Working with care and dedication, we’re developing new therapies that address the greatest needs in healthcare, making bold strides in cancer and other diseases.

Learn More About Our Medicines

New Home With Purpose

Work with a Purpose

Be part of something extraordinary. Our people are our most important asset, and we enable them to bring their best selves to work.

Join Our Team
Office employee sitting listening to conversation